- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.02. | Spago Nanomedical Year-End Report January-December, 2025 | 274 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 4 (KSEK 617)The loss for the quarter... ► Artikel lesen | |
| 08.12.25 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2026 | 245 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 8, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue | 291 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 07.11.25 | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 356 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 06.11.25 | Spago Nanomedical AB: Spago Nanomedical publishes information document in connection with forthcoming rights issue | 189 | GlobeNewswire (Europe) | The board of directors of Spago Nanomedical AB (publ) ("Spago Nanomedical" or "the Company") has today published an information document in connection with the Company's new share issue with rights... ► Artikel lesen | |
| 03.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.11.2025 | 418 | Xetra Newsboard | Das Instrument GW3 SE0009155518 GAPWAVES AB CLASS B O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 03.11.2025 und ex Kapitalmassnahme am 04.11.2025 The instrument GW3 SE0009155518 GAPWAVES AB CLASS... ► Artikel lesen | |
| 29.10.25 | Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad | 307 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 29.10.25 | Spago Nanomedical Interim Report January-September 2025 | 280 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 29, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 14 (KSEK 485)The loss for the quarter amounted... ► Artikel lesen | |
| 14.10.25 | Visible Tumor Uptake and Recommended Dose Increase in Spago Nanomedicals's Phase I/IIa Study Tumorad-01 | 232 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 14, 2025 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends a dose increase... ► Artikel lesen | |
| 20.08.25 | Spago Nanomedical Interim Report January-June, 2025 | 333 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)APRIL - JUNE IN BRIEFNet sales for the quarter amounted to KSEK 81 (KSEK 459)The loss for the quarter amounted... ► Artikel lesen | |
| 03.06.25 | Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation | 334 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing... ► Artikel lesen | |
| 14.05.25 | Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB | 365 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the AGM... ► Artikel lesen | |
| 07.05.25 | Spago Nanomedical Interim Report January-March, 2025 | 407 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 338 (KSEK 350)The loss for the quarter amounted... ► Artikel lesen | |
| 15.04.25 | Spago Nanomedical Publishes The Annual Report for 2024 | 403 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2024 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 09.04.25 | Notice To Annual General Meeting of Spago Nanomedical AB | 412 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version... ► Artikel lesen | |
| 20.03.25 | Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical's Board | 742 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board... ► Artikel lesen | |
| 04.03.25 | Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01 | 443 | ACCESS Newswire | LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,700 | -1,44 % | Shortseller-Positionen aktuell: freenet, GFT, HelloFresh, Hypoport, Puma, Qiagen, Redcare Pharmacy | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | 0,00 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| VERA THERAPEUTICS | 40,420 | 0,00 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| BIONTECH | 87,50 | -4,94 % | BioNTech SE: BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 24. Februar 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 10. März 2026, die Ergebnisse für das vierte Quartal und... ► Artikel lesen | |
| EVOTEC | 5,304 | -6,72 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| TREVI THERAPEUTICS | 12,570 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,92 | 0,00 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| PRAXIS PRECISION MEDICINES | 330,19 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 32,520 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,680 | 0,00 % | Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential | ||
| KINIKSA PHARMACEUTICALS | 46,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,890 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,145 | +3,36 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,190 | 0,00 % | H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty |
Das Unternehmen SPAGO NANOMEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,009 Euro und damit +4,65 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.